SETD2 and colorectal carcinoma: These findings reveal criticalmolecular and prognostic differences between LCC and RCC and highlight SMAD4 and SETD2 asimportant prognostic biomarkers, suggesting the potential value of location‐and mutation‐guided precision therapies in CRC.